BillionToOne

Founded in 2016 by , , and , BillionToOne is a DNA diagnostic company originating from 's . It is located in , and uses diagnostic testing that quantifies molecular level bodily changes.

COVID-19 Response

BillionToOne received emergency use authorization from the (FDA) in 2020, for its SARS-CoV-2 test that removes the process of () extraction, a time-consuming step in testing. BillionToOne developed a COVID-19 testing method called the qSanger-COVID-19 assay. It uses different instrument sets and chemicals than other methods that were applied in 2020. BillionToOne partnered with SwiftBiosciences to manufacture the COVID-19 assay kits and began international distribution in May of 2020.

qSanger

qSanger^TM technology is a patent-pending test developed by BillionToOne that works to detect viral RNA. It is based on the technology in Sanger sequencing, a DNA testing method that determines the nucleotide sequence in DNA molecules, also known as the "chain termination method."

Timeline

July 12, 2021

BillionToOne closes $55,000,000 Series B Funding round led by Hummingbird Ventures and Four Rivers Group with participation from Neotribe Ventures, Norwest Venture Partners, Y Combinator, and Libertus Capital.

July 12, 2021

BillionToOne raises a $55,000,000 series B round.

March 2020

BillionToOne raises a $15,000,000 series A round from 500 Startups Istanbul, Andrea Dusi, Civilization Ventures, Friále, HOF Capital, Hummingbird Ventures, Libertus Capital, NeoTribe Ventures, Pacific 8 Ventures and Y Combinator.

March 13, 2019

BillionToOne raises a $15,000,000 series A round from 500 Startups, Civilization Ventures, Fifty Years, HOF Capital, Hummingbird Ventures, NeoTribe Ventures and Y Combinator.

September 15, 2017

BillionToOne raises a $2,400,000 seed round from Friále, NewDo Venture, UpHonest Capital and Wei Guo.

August 2017

BillionToOne raises a $120,000 seed round from Y Combinator.

January 2016

BillionToOne was founded by Dave Tsao, Oguzhan Atay and Sukrit Silas.